What is Benchling?
Benchling operates as a premier cloud-based platform designed to support the entire lifecycle of scientific research and development. Originally conceived in an academic environment to address the lack of specialized tools for complex biological data, the company has evolved into an essential partner for biotech leaders, pharmaceutical giants, and emerging innovators. Its software suite facilitates the management of experimental data, sample tracking, and collaborative research, effectively replacing fragmented legacy systems with a cohesive, scalable digital architecture. By centralizing critical R&D information, Benchling enables organizations to accelerate the development of new medicines, sustainable materials, and agricultural advancements, thereby serving as the backbone for the modern biotech revolution.
How much funding has Benchling raised?
Benchling has raised a total of $418.9M across 9 funding rounds:
Angel/Seed
$900K
Unspecified
$5M
Private Equity
$7M
Series A
$7M
Series B
$14.5M
Series C
$34.5M
Series D
$50M
Series E
$200M
Series F
$100M
Angel/Seed (2014): $900K with participation from Y Combinator and Rock Health companies
Unspecified (2015): $5M led by Thrive Capital and Andreessen Horowitz
Private Equity (2016): $7M supported by Andreessen Horowitz and Thrive Capital
Series A (2016): $7M featuring Thrive Capital, Ashton Kutcher Network, Andreessen Horowitz, Geoff Ralston, and Matt Huang
Series B (2018): $14.5M backed by F-Prime Capital Partners, Benchmark Capital, and Thrive Capital
Series C (2019): $34.5M with participation from Menlo Ventures, Lead Edge Capital Management, Benchmark, Y Combinator Continuity, and Thrive Capital
Series D (2020): $50M led by ICONIQ Partners, Spark Capital, Benchmark, Lux Capital, Alkeon Capital Management LLC, and Thrive Capital
Series E (2021): $200M supported by Altimeter Capital, Benchmark Holdings, Sequoia Capital Global Equities, Byerly Capital, ICONIQ Capital, Spark Capital, Alkeon Capital Management, Menlo Ventures, Lead Edge Capital Management, Lux Capital, Thrive Capital, and Elad Gil
Series F (2021): $100M, investors not publicly disclosed
Key Investors in Benchling
Thrive Capital
Thrive Capital is an investment venture capital company that operates out of New York. Thrive Capital primarily deals in internet and software investments.
Andreessen Horowitz
A prominent venture capital firm that invests in software-eating-the-world companies, providing deep expertise in scaling technology platforms.
Benchmark
A premier venture capital firm known for its early-stage investments in transformative technology companies and its hands-on approach to board-level guidance.
What's next for Benchling?
With the infusion of recent capital, Benchling is well-positioned to deepen its market penetration and enhance its product suite to meet the evolving needs of the global scientific community. The company is expected to prioritize the expansion of its enterprise-grade features, focusing on advanced analytics, cross-functional integration, and compliance capabilities that are essential for large-scale pharmaceutical operations. Furthermore, the strategic deployment of these funds will likely support the company's mission to democratize access to high-performance R&D tools, ensuring that both small-scale startups and multinational corporations can leverage the power of biotechnology to solve the world's most pressing challenges. As the company continues to scale, its focus will remain on driving operational excellence and fostering a robust ecosystem for scientific discovery.
See full Benchling company page
